1.郑州颐和医院心血管内科,郑州 450000
2.河南中医药大学第一附属医院心血管内科,郑州 450003
3.郑州大学第一附属医院中西医结合科,郑州 450040
4.锦州医科大学附属第一医院老年医学科,辽宁 锦州 121001
Received:08 July 2026,
Revised:2026-10-19,
Accepted:19 October 2026,
Published:30 October 2026
移动端阅览
贺茜影,卫靖靖,马腾,等.纳米载体药物递送系统在动脉粥样硬化治疗中的研究进展 [J].中国药房,2026,37(20):2759-2764.
HE Xiying,WEI Jingjing,MA Teng,et al.Research progress of nanocarrier-based drug delivery systems in the treatment of atherosclerosis[J].ZHONGGUO YAOFANG,2026,37(20):2759-2764.
贺茜影,卫靖靖,马腾,等.纳米载体药物递送系统在动脉粥样硬化治疗中的研究进展 [J].中国药房,2026,37(20):2759-2764. DOI: 10.6039/j.issn.1001-0408.2026.20.21.
HE Xiying,WEI Jingjing,MA Teng,et al.Research progress of nanocarrier-based drug delivery systems in the treatment of atherosclerosis[J].ZHONGGUO YAOFANG,2026,37(20):2759-2764. DOI: 10.6039/j.issn.1001-0408.2026.20.21.
纳米载体药物递送系统可通过调控药物的体内分布与释放行为,为动脉粥样硬化(AS)的病灶靶向干预提供新的研究策略。现有研究表明,聚合物与脂质纳米载体、细胞膜包裹系统及微环境响应型递药策略可通过调节巨噬细胞功能、促进胆固醇外排、控制炎症与氧化应激等途径干预AS的病理进程,部分递药系统尝试通过联合递送和诊疗一体化实现多靶点协同干预,还有部分纳米载体药物递送系统通过提高病灶药物富集来调节相关病理过程,但其长期安全性、病灶靶向稳定性、规模化制备及临床增量获益仍有待验证。未来需加强递送机制与病理特征的匹配,建立药动学和安全性的评价体系,为纳米载体药物递送系统的临床转化提供依据。
Nanocarrier-based drug delivery systems can provide new research strategies for targeted intervention at atherosclerosis (AS) lesions by regulating the
in vivo
distribution and release behavior of drugs. Existing studies have shown that polymeric and lipid nanocarriers, cell membrane-coated systems, and microenvironment-responsive drug delivery strategies can intervene in the pathological progression of AS by modulating macrophage function, promoting cholesterol efflux, and controlling inflammation and oxidative stress; some systems have attempted to achieve multi-target synergistic intervention through combined delivery and theranostics; some drug delivery systems can improve drug enrichment in lesions and modulate related pathological processes. However, their long-term safety, lesion-targeting stability, scale-up ma
nufacturing, and incremental clinical benefit remain to be validated. In the future, it is necessary to strengthen the matching between delivery mechanisms and pathological features and to establish evaluation systems for pharmacokinetics and safety, thereby providing a basis for the clinical translation of nanocarrier-based drug delivery systems.
Garrido A M , Kaistha A , Uryga A K , et al . Efficacy and limitations of senolysis in atherosclerosis [J ] . Cardiovasc Res , 2022 , 118 ( 7 ): 1713 - 1727 .
Li N , Pi C , Zhu S Y , et al . Opportunities for the treatment of atherosclerosis:selectins [J ] . Pharmacol Res , 2025 , 217 : 107807 .
Liu S J , Yao J K , Huang H Y , et al . Endothelial MerTK impairment accelerates the development of atherosclerosis [J ] . Redox Biol , 2025 , 87 : 103861 .
Alotaibi B S , Buabeid M , Ibrahim N A , et al . Potential of nanocarrier-based drug delivery systems for brain tar-geting:a current review of literature [J ] . Int J Nanomed , 2021 , 16 : 7517 - 7533 .
王婷婷 , 于莉莉 , 周阳 , 等 . 纳米技术在动脉粥样硬化治疗中最新进展 [J ] . 中华老年心脑血管病杂志 , 2023 , 25 ( 6 ): 658 - 660 .
陈亮 , 吴彪 , 袁良喜 . 基于纳米材料的递送系统在动脉粥样硬化诊疗中的应用进展 [J ] . 上海交通大学学报(医学版) , 2025 , 45 ( 12 ): 1687 - 1693 .
Mendieta G , Pocock S , Mass V , et al . Determinants of progression and regression of subclinical atherosclerosis over 6 years [J ] . J Am Coll Cardiol , 2023 , 82 ( 22 ): 2069 - 2083 .
Zhao F , Shao M Y , Li M R , et al . Sphingolipid metabolites involved in the pathogenesis of atherosclerosis:pers-pectives on sphingolipids in atherosclerosis [J ] . Cell Mol Biol Lett , 2025 , 30 ( 1 ): 18 .
Seijkens T T P , van Tiel C M , Kusters P J H , et al . Tar-geting CD40-induced TRAF6 signaling in macrophages reduces atherosclerosis [J ] . J Am Coll Cardiol , 2018 , 71 ( 5 ): 527 - 542 .
Zhang J H , Tong J R , Sun Y , et al . How advanced is nanomedicine to treat atherosclerosis? A comprehensive review of the literature [J ] . Int J Nanomed , 2026 , 21 : 563561 .
Cicha I , Chauvierre C , Texier I , et al . From design to the clinic:practical guidelines for translating cardiovascular nanomedicine [J ] . Cardiovasc Res , 2018 , 114 ( 13 ): 1714 - 1727 .
Đorđević S , Gonzalez M M , Conejos-Sánchez I , et al . Current hurdles to the translation of nanomedicines from bench to the clinic [J ] . Drug Deliv Transl Res , 2022 , 12 ( 3 ): 500 - 525 .
Mahmoud K , Swidan S , El-Nabarawi M , et al . Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma:a comprehensive review on targeting and recent advances [J ] . J Nanobiotechnol , 2022 , 20 ( 1 ): 109 .
Nele V , Campani V , Alia Moosavian S , et al . Lipid nanoparticles for RNA delivery:self-assembling vs. driven-assembling strategies [J ] . Adv Drug Deliv Rev , 2024 , 208 : 115291 .
Gunawan M , Boonkanokwong V . Current applications of solid lipid nanoparticles and nanostructured lipid carriers as vehicles in oral delivery systems for antioxidant nutraceuticals:a review [J ] . Colloids Surf B Biointerfaces , 2024 , 233 : 113608 .
Wu Y Z , Zhou H Y , Liu H , et al . Pitavastatin-loaded procyanidins self-assembled nanoparticles alleviate advanced atherosclerosis via modulating macrophage efferocytosis and cholesterol efflux [J ] . Acta Pharm Sin B , 2025 , 15 ( 6 ): 3305 - 3320 .
Kim H , Kumar S , Kang D W , et al . Affinity-driven design of cargo-switching nanoparticles to leverage a cholesterol-rich microenvironment for atherosclerosis therapy [J ] . ACS Nano , 2020 , 14 ( 6 ): 6519 - 6531 .
Luo Y H , Guo Y H , Wang H L , et al . Phospholipid nanoparticles:therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation [J ] . EBioMedicine , 2021 , 74 : 103725 .
Lopes J , Lopes D , Pereira-Silva M , et al . Macrophage cell membrane-cloaked nanoplatforms for biomedical applications [J ] . Small Meth , 2022 , 6 ( 8 ): 2200289 .
Desai N , Rana D , Pande S , et al . “Bioinspired” membrane-coated nanosystems in cancer theranostics:a comprehensive review [J ] . Pharmaceutics , 2023 , 15 ( 6 ): 1677 .
Gao C , Huang Q X , Liu C H , et al . Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines [J ] . Nat Commun , 2020 , 11 ( 1 ): 2622 .
Sui Y C , Sun X Y , Liu Q , et al . Mori fructus-derived extracellular vesicle-like nanoparticles regulate dyslipidemia and prevent atherosclerosis progression via miRNAs [J ] . Phytomedicine , 2025 , 146 : 157128 .
Fontana F , Molinaro G , Moroni S , et al . Biomimetic platelet-cloaked nanoparticles for the delivery of anti-inflammatory curcumin in the treatment of atherosclerosis [J ] . Adv Healthc Mater , 2024 , 13 ( 15 ): e2302074 .
Joglekar M , Trewyn B G . Polymer-based stimuli-responsive nanosystems for biomedical applications [J ] . Biotechnol J , 2013 , 8 ( 8 ): 931 - 945 .
Wei D S , Sun Y , Zhu H , et al . Stimuli-responsive polymer-based nanosystems for cancer theranostics [J ] . ACS Nano , 2023 , 17 ( 23 ): 23223 - 23261 .
Das B . Transition metal complex-loaded nanosystems:advances in stimuli-responsive cancer therapies [J ] . Small , 2025 , 21 ( 7 ): 2410338 .
Wu M , Chen M J , Zhao Y Z , et al . Neutrophil hitchhiking-mediated delivery of ROS-scavenging biomimetic nanoparticles for enhanced treatment of atherosclerosis [J ] . Small Meth , 2025 , 9 ( 7 ): 2402019 .
Fang F , Ni Y H , Yu H C , et al . Inflammatory endothelium-targeted and cathepsin responsive nanoparticles are effective against atherosclerosis [J ] . Theranostics , 2022 , 12 ( 9 ): 4200 - 4220 .
Wang A Q , Yue K , Yan X T , et al . Inhibition of platelet adhesion to exposed subendothelial collagen by steric hindrance with blocking peptide nanoparticles [J ] . Colloids Surf B Biointerfaces , 2024 , 237 : 113866 .
Qiu S , Liu J H , Chen J M , et al . Targeted delivery of MerTK protein via cell membrane engineered nanoparticle enhances efferocytosis and attenuates atherosclerosis in diabetic ApoE -/- Mice [J ] . J Nanobiotechnol , 2024 , 22 ( 1 ): 178 .
Fernández-Friera L , Fuster V , López-Melgar B , et al . Normal LDL-cholesterol levels are associated with subclinical atherosclerosis in the absence of risk factors [J ] . J Am Coll Cardiol , 2017 , 70 ( 24 ): 2979 - 2991 .
Zhu L , Li H J , Li J Y , et al . Biomimetic nanoparticles to enhance the reverse cholesterol transport for selectively inhibiting development into foam cell in atherosclerosis [J ] . J Nanobiotechnol , 2023 , 21 ( 1 ): 307 .
Jiang T , Xu L , Zhao M X , et al . Dual targeted delivery of statins and nucleic acids by chitosan-based nanoparticles for enhanced antiatherosclerotic efficacy [J ] . Biomaterials , 2022 , 280 : 121324 .
Zhou Q R , Huang M Q , Wang Y J , et al . Platelet membrane biomimetic chemiluminescent nanoparticles for targeted therapy of atherosclerosis [J ] . ACS Appl Mater Interfaces , 2025 , 17 ( 33 ): 46680 - 46692 .
Tang D , Wang Y , Wijaya A , et al . ROS-responsive biomimetic nanoparticles for potential application in targeted anti-atherosclerosis [J ] . Regen Biomater , 2021 , 8 ( 4 ): rbab033 .
Zhou H Y , You P D , Liu H , et al . Artemisinin and procyanidins loaded multifunctional nano complexes alleviate atherosclerosis via simultaneously modulating lipid influx and cholesterol efflux [J ] . J Control Release , 2022 , 341 : 828 - 843 .
Ahmadi A , Argulian E , Leipsic J , et al . From subclinical atherosclerosis to plaque progression and acute coronary events:JACC state-of-the-art review [J ] . J Am Coll Cardiol , 2019 , 74 ( 12 ): 1608 - 1617 .
He J N , Cai J X , Zhang J J , et al . Enhanced atherosclerosis molecular imaging and therapy with collagen hybridizing peptide functionalized albumin nanoparticles [J ] . J Nanobiotechnol , 2025 , 23 ( 1 ): 691 .
Nankivell V A , Sandeman L , Stretton L , et al . Theranostic porphyrin nanoparticles identify atherosclerosis via multimodal imaging and elicit atheroprotective effects [J ] . Mater Today Bio , 2025 , 34 : 102202 .
Segers F M E , Ruder A V , Westra M M , et al . Magnetic resonance imaging contrast-enhancement with superparamagnetic iron oxide nanoparticles amplifies macrophage foam cell apoptosis in human and murine atherosclerosis [J ] . Cardiovasc Res , 2023 , 118 ( 17 ): 3346 - 3359 .
Deng Y P , Deng X , Li Y , et al . Size-adjustable nanoparticles co-target macrophages and endothelial cells for enhanced atherosclerosis therapy [J ] . Colloids Surf B Biointerfaces , 2025 , 255 : 114952 .
Cheng M Y , Yue T X , Wang H , et al . Biomimetic nanoparticles co-deliver hirudin and lumbrukinase to ameliorate thrombus and inflammation for atherosclerosis therapy [J ] . Asian J Pharm Sci , 2025 , 20 ( 1 ): 100990 .
Dash R , Yadav M , Biswal J , et al . Modeling of chitosan modified PLGA atorvastatin-curcumin conjugate(AT-CU)nanoparticles,overcoming the barriers associated with PLGA:an approach for better management of atherosclerosis [J ] . Int J Pharm , 2023 , 640 : 123009 .
Virani S S , Newby L K , Arnold S V , et al . 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease:a report of the American Heart Association/American College of Cardiology Joint Committee on clinical practice guidelines [J ] . Circulation , 2023 , 148 ( 9 ): e9 - e119 .
0
Views
0
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution
京公网安备11010802024621
